

## TO THE EDITOR:

## Pevedonistat with azacitidine in older patients with *TP53*-mutated AML: a phase 2 study with laboratory correlates

Antoine N. Saliba,<sup>1</sup> Scott H. Kaufmann,<sup>1-3</sup> Eytan M. Stein,<sup>4</sup> Prapti A. Patel,<sup>5</sup> Maria R. Baer,<sup>6</sup> Wendy Stock,<sup>7</sup> Michael Deininger,<sup>8</sup> William Blum,<sup>9</sup> Gary J. Schiller,<sup>10</sup> Rebecca L. Olin,<sup>11</sup> Mark R. Litzow,<sup>1</sup> Tara L. Lin,<sup>12</sup> Brian J. Ball,<sup>13</sup> Michael M. Boyiadzis,<sup>14</sup> Elie Traer,<sup>15</sup> Olatoyosi Odenike,<sup>7</sup> Martha L. Arellano,<sup>9</sup> Alison Walker,<sup>16</sup> Vu H. Duong,<sup>6</sup> Tibor Kovacovics,<sup>8</sup> Robert H. Collins,<sup>5</sup> Abigail B. Shoben,<sup>16</sup> Nyla A. Heerema,<sup>16</sup> Matthew C. Foster,<sup>17</sup> Kevin L. Peterson,<sup>1,2</sup> Paula A. Schneider,<sup>1,2</sup> Molly Martycz,<sup>16</sup> Theophilus J. Gana,<sup>18</sup> Leonard Rosenberg,<sup>19</sup> Sonja Marcus,<sup>19</sup> Ashley O. Yocum,<sup>19</sup> Timothy Chen,<sup>16</sup> Mona Stefanos,<sup>16</sup> Alice S. Mims,<sup>16</sup> Uma Borate,<sup>16</sup> Amy Burd,<sup>19</sup> Brian J. Druker,<sup>15</sup> Ross L. Levine,<sup>4</sup> John C. Byrd,<sup>20</sup> and James M. Foran<sup>21</sup>

<sup>1</sup>Division of Hematology, Department of Medicine, <sup>2</sup>Division of Oncology Research, Department of Oncology, and <sup>3</sup>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN; <sup>4</sup>Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>5</sup>Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX; <sup>6</sup>University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD; <sup>7</sup>Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL; <sup>8</sup>Division of Hematology and Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; <sup>9</sup>Winship Cancer Institute of Emory University, Atlanta, GA; <sup>10</sup>David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; <sup>11</sup>University of California, San Francisco, San Francisco, CA; <sup>12</sup>Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; <sup>13</sup>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA; <sup>14</sup>University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA; <sup>15</sup>Knight Cancer Institute, Oregon Health & Science University, Portland, OR; <sup>16</sup>The Ohio State University, Columbus, OH; <sup>17</sup>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; <sup>18</sup>Biopharmatech Consulting, Inc., Leesburg, VA; <sup>19</sup>Leukemia and Lymphoma Society, White Plains, NY; <sup>20</sup>Department of Medicine, University of Cincinnati, Cincinnati, OH; and <sup>21</sup>Division of Hematology-Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL

Finding safe and effective treatment strategies for patients with *TP53*-mutated acute myeloid leukemia (AML) remains an important unmet need.<sup>1,2</sup> Among all somatic mutations found in AML, *TP53* mutations are associated with intrinsic resistance to cytotoxic therapy, shorter overall survival (OS), and inferior outcomes with allogeneic hematopoietic cell transplantation.<sup>3-6</sup> The NEDD8-activating enzyme inhibitor pevedonistat (PEVO) has been shown to induce apoptosis in AML via increased reactive oxygen species<sup>7</sup> as well as accumulation of the oncoprotein MYC and transactivation of the gene encoding the BH3-only protein NOXA in AML cell lines and primary AML samples.<sup>8</sup> Additional studies have demonstrated that PEVO enhances the cytotoxicity of hypomethylating agents in preclinical AML models.<sup>9</sup> Consistent with these observations, a phase 1b study of PEVO with azacitidine (AZA) demonstrated a composite complete remission (CCR) rate of 30%, with an additional 11% partial remission rate. Responses occurred irrespective of poor-risk disease features and were observed in 6 of 8 patients with *TP53*-mutated AML.<sup>10</sup> Here, we report the results of a phase 2 study of PEVO + AZA in older patients with previously untreated *TP53*-mutated AML that builds on the previous results. This was a substudy of the Beat AML “umbrella” Master trial ([www.clinicaltrials.gov](http://www.clinicaltrials.gov), #NCT03013998) evaluating targeted therapies using prospective genomic profiling of previously untreated older patients with AML.<sup>11</sup>

The primary objective of this open-label phase 2 study was to evaluate the CCR rate (complete remission [CR] + CR with incomplete hematologic recovery [CRi]) and tolerability of PEVO + AZA combination therapy in patients  $\geq 60$  years of age with untreated *TP53*-mutated AML (variant allele frequency [VAF]  $\geq 30\%$ ). Inclusion criteria are listed in supplemental Table 1. This study was approved by a central institutional review board and by local institutional review boards and was conducted according to the Declaration of Helsinki. Four sites enrolled  $\geq 1$  patient(s) between April 2018 and December 2019. AZA (75 mg/m<sup>2</sup>) was administered subcutaneously or intravenously on days 1 to 7 (or days 1-5 and days 8 and 9) of every 28-day cycle for up to 12 cycles. PEVO (20 mg/m<sup>2</sup>) was given as a

Submitted 22 July 2022; accepted 5 October 2022; prepublished online on *Blood Advances* First Edition 31 October 2022; final version published online 25 May 2023.  
<https://doi.org/10.1182/bloodadvances.2022008625>.

Data are available on request from the corresponding author, Antoine N. Saliba ([antoine.nabil.saliba@gmail.com](mailto:antoine.nabil.saliba@gmail.com) and [saliba.antoine@mayo.edu](mailto:saliba.antoine@mayo.edu)).

The full-text version of this article contains a data supplement.

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

**Table 1. Patient demographics and baseline characteristics**

	Total, N = 10
<b>Age, y</b>	
Median (range)	72.0 (68.0-85.0)
<b>Sex, n (%)</b>	
Male	5 (50.0)
Female	5 (50.0)
<b>Race, n (%)</b>	
White	9 (90.0)
Other	1 (10.0)
<b>Ethnicity, n (%)</b>	
Hispanic or Latino	0
Not Hispanic or Latino	10 (100.0)
<b>Body mass index (kg/m<sup>2</sup>)</b>	
Median (range)	28.42 (20.7-38.6)
Previous exposure to chemotherapy for an indication other than AML, n (%)	3 (30.0)
Previous exposure to radiation therapy, n (%)	4 (40.0)


n, number of patients in subset.

1-hour infusion on days 1, 3, and 5 of each cycle for up to 24 cycles after administration of AZA. Bone marrow aspiration and biopsy were performed before therapy and after 1, 2, and 4 cycles to assess clinical response using the 2017 European LeukemiaNet criteria.<sup>12</sup> The primary end point was the proportion of patients with CCR by the end of cycle 4. Secondary end points included response duration, OS, and proportion of patients transitioning to allogeneic hematopoietic cell transplantation. This study used Simon's Optimal 2-stage design. The statistical methods are summarized in Supplemental Table 2.

After the enrollment, 10 patients received treatment with both the study drugs. The baseline demographics/characteristics of these patients are summarized in Table 1 and supplemental Table 3. Patients completed a median of 3.5 (range, 2-13) cycles of PEVO + AZA over a median of 81 days. Three patients (30%) completed more than 6 cycles.

All patients were clinically followed up for response (Figure 1). Nine patients were assessed for the primary end point; none attained CCR by the end of cycle 4. Two patients attained partial remission (patients 3 and 7, shown in supplemental Table 3) and 7 patients (70%) had stable disease by the end of cycle 4. Because the ≥40% CCR rate required for continuing enrollment after stage 1 was not reached, the futility of the PEVO + AZA combination was declared, and enrollment was stopped. Notably, however, 1 patient (patient 6) attained CR with incomplete hematologic recovery by the beginning of cycle 6 but subsequently progressed at cycle 9, day 1. When compared with the other 9 patients, unique characteristics of this patient's AML included mutations in *BRCA2* (VAF, 45.71%), *TET2* (VAF, 49.34%), *CSF1R* (VAF, 53.73%), *MDM2* (VAF, 50.54%), and *ASXL1* (42.71%). The median OS was 187.5 days (95% confidence interval, 31.0-326.0) (supplemental Figure 1).

All patients treated in the study experienced at least 1 treatment-emergent adverse event (TEAE). Overall, 9 patients (90%) experienced grade 3 or higher TEAEs. Two patients (20%) had treatment-emergent serious adverse events (SAEs) that resulted in death (grade 5 respiratory failure and an unknown cause) and were considered unrelated to the study therapy. The most common grade 3 or higher TEAE was grade 4 neutropenia in 2 patients (20%). Three patients experienced the following 6 additional treatment-emergent SAEs: grade 3 pleural effusion, grade 2 posterior tibial and peroneal vein thrombosis, grade 3 pneumonia, grade 3 cellulitis, grade 3 small intestine obstruction, and grade 4 sepsis. All patients died during the study; the most common



**Figure 1. Swimmer's plot of the 10 patients who received study treatment with PEVO and AZA.** Rectangles surrounding patient numbers indicate the reason for the discontinuation of study treatment. Created with [www.biorender.com](http://www.biorender.com).

causes of death were AML progression (60%) and SAEs which resulted in the death of 2 patients (20%).

The response rate in this study was lower than in the phase 1b study.<sup>10</sup> One reason may be that this study enrolled patients with *TP53*-mutated AMLs with a VAF  $\geq 30\%$  to assure treatment of dominant clones, whereas a lower VAF was used to classify the disease as *TP53*-mutated in the phase 1b study.<sup>10</sup> Importantly, a higher *TP53* VAF has been associated with similarly poor survival outcomes with hypomethylating agent treatment.<sup>13</sup>

Among the planned correlative studies was immunoblotting to examine changes in BCL2 family members and DNMT1 throughout the treatment. These proteins were studied in the 12 available samples from 5 patients because (1) BCL2 family members, which mediate most chemotherapy-induced killing,<sup>14</sup> are modulated by the study drugs<sup>8,15</sup> and (2) DNMT1, the most abundantly expressed DNA methyltransferase in proliferating cells and a potential oncoprotein in AML,<sup>16</sup> has been reported to be higher in AZA-resistant AML cells<sup>17</sup> and lower in AML that responds to decitabine.<sup>18</sup> Consistent with preclinical observations,<sup>8</sup> the proapoptotic BCL2 family member NOXA was upregulated at the end of cycle 1 in 4 of 5 patients (supplemental Figure 2). NOXA upregulation was associated with the upregulation of additional BH3-only proteins, including PUMA, BIM, and BID. Importantly, though BCL2 was unchanged, upregulation of the antiapoptotic proteins BCLX<sub>L</sub> and MCL1 was also observed at the end of cycle 1 compared with baseline in all patients, providing a potential explanation for the ability of blasts to tolerate increased BH3-only protein levels. Given the small sample size and low response rate, it is difficult to draw definitive conclusions about any differences between patients. Although PEVO and AZA have both been reported to increase NOXA expression,<sup>8,15</sup> the short half-life of these drugs (<10 hours) makes it important to look at the changes in pro- and antiapoptotic BCL2 family members at time points closer to therapy with those agents in future studies. In this study, DNMT1 levels also increased at the end of cycle 1 in 4 of 5 patients. However, conclusions about the predictive value of baseline DNMT1 levels cannot be made based on our study because most patients did not achieve a response.

In summary, in this phase 2 Beat AML substudy, treatment with AZA + PEVO did not induce responses (CCR) in older patients with *TP53*-mutated AML. These observations mirror recent results with the same combination in myelodysplastic syndrome,<sup>19</sup> stand in contrast to previous results in AML,<sup>10</sup> and do not support the combination as targeted therapy in *TP53*-mutated AML. Reports of studies (#NCT04172844 and #NCT03862157) examining the addition of venetoclax to AZA + PEVO in AML are eagerly awaited.

**Acknowledgments:** The work was supported by the Leukemia & Lymphoma Society and by grants from the National Cancer Institute, National Institutes of Health (R01 CA225996) (S.H.K.) and the National Cancer Institute, National Institutes of Health (R35 CA198183 and support grant P30 CA008748) (J.C.B.).

**Contribution:** A.N.S. and S.H.K. wrote the manuscript; A.N.S., S.H.K., A.B.S., A.O.Y., T.C., M.S., A.S.M., U.B., A.B., B.J.D., R.L.L., J.C.B., and J.M.F. designed research; A.N.S., S.H.K., E.M.S., P.A.P., M.R.B., W.S., M.D., W.B., G.J.S., R.L.O., M.R.L., T.L.L., B.J.B.,

M.M.B., E.T., O.O., M.L.A., A.W., V.H.D., T.K., R.H.C., M.C.F., K.L.P., P.A.S., A.S.M., U.B., B.J.D., R.L.L., J.C.B., and J.M.F. performed research; A.N.S., E.M.S., P.A.P., M.R.B., W.S., M.D., W.B., G.J.S., R.L.O., M.R.L., T.L.L., B.J.B., M.M.B., E.T., O.O., M.L.A., A.W., V.H.D., T.K., R.H.C., M.C.F., K.L.P., P.A.S., M.M., L.R., S.M., A.O.Y., T.C., M.S., A.S.M., U.B., B.J.D., R.L.L., J.C.B., and J.M.F. collected data; A.N.S., S.H.K., N.A.H., M.M., T.J.G., L.R., S.M., A.O.Y., T.C., and M.S. analyzed and interpreted data; and all authors reviewed and edited the manuscript.

**Conflict-of-interest disclosure:** S.H.K. has previously received funding from Eli Lilly and Takeda. E.M.S. has served on the advisory boards of Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Amgen, Seattle Genetics, Syros Pharmaceuticals, Syndax Pharmaceuticals, Agios Pharmaceuticals, and Celgene and is an equity holder in Auron Therapeutics. P.A.P. has served on the advisory board of Agios Pharmaceuticals. M.D. has served on the advisory boards of Blueprint Medicines, Takeda, Incyte Corporation, and Sangamo Therapeutics; has been a consultant for Blueprint Medicines, Fusion Pharmaceuticals, Medscape, Novartis, Sangamo Therapeutics, and DisperSol Technologies; has received research funding from Blueprint Medicines, Takeda, Novartis, Incyte Corporation, Sun Pharma Advanced Research Company, and Pfizer; and has served on the study management committees of Blueprint Medicines and Takeda. G.J.S. reports research funds paid for medical research (eg, collaborative research, funded research, and clinical trial) by 1 commercial entity, if the sum of which a presenter (presenters) is in the position to decide how to use is 1 million yen or more per year for Takeda. R.L.O. receives research funding from Cellectis, Astellas, and Pfizer and is a consultant for Actinium, Astellas, and AbbVie. M.M.B. is employed by Genentech. E.T. has served on the advisory boards of AbbVie, Astellas Pharma, Genentech, Agios Pharmaceuticals, and Daiichi Sankyo; has received clinical trial support from Janssen Pharmaceuticals; receives clinical trial funding and sponsored research from Incyte Corporation; and holds equity in notable laboratories. O.O. has served on the advisory boards of AbbVie, Celgene, and Impact Biomedicines and has received research funding from AbbVie, AstraZeneca, Astex, Agios Pharmaceuticals, Celgene, CTI BioPharma, Incyte Corporation, Janssen Pharmaceuticals, Kartos Therapeutics, NS Pharma, and OTS. M.C.F. receives consulting fees from Daiichi Sankyo, MacroGenics, and Zentalis Pharmaceuticals and research funding from Bellicum Pharmaceuticals, Bristol-Myers Squibb/Celgene, Rafael Pharmaceuticals, LOXO/Lilly Oncology, Newave Pharmaceuticals, and MacroGenics. T.J.G. is a clinical consultant for Leukemia & Lymphoma Society, which receives funding from AbbVie, Agios Pharmaceuticals, Alexion Pharmaceuticals, Amgen, Astellas Pharma, AstraZeneca, Boehringer Ingelheim International, Boston Biomedical, Bristol-Myers Squibb, Celgene, Genentech, Gilead Sciences, ImmunoGen, Jazz Pharmaceuticals, Johnson & Johnson, Novartis, Pfizer, Pharmacyclics, RTI Health Solutions, Shire, and Takeda. L.R., S.M., A.O.Y., and A.B. are employees of Leukemia & Lymphoma Society. A.S.M. has served on the advisory boards of Jazz Pharmaceuticals, AbbVie/Genentech, Astellas Pharma, PTC Therapeutics, Novartis, Agios Pharmaceuticals, and Syndax Pharmaceuticals. U.B. has been a consultant for Genentech, Daiichi Sankyo, Takeda, Pfizer, AbbVie/Genentech, and Novartis. B.J.D. has served on the scientific advisory boards for

Adela Bio, Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Celgene, RUNX1 Research Program, Nemucore Medical Innovations, Novartis, and Vivid Biosciences (inactive); has served on the scientific advisory boards and stock for Aptose Biosciences, Blueprint Medicines, Enliven Therapeutics, Iterion Therapeutics, GRAIL, and Recludix Pharma; has served on the board of directors and stock for Amgen and Vincerx Pharma; has served on the board of directors for Burroughs Wellcome Fund, and CureOne; has served on the joint steering committee for Beat AML LLS; is the founder of VB Therapeutics; is in a sponsored research agreement with Enliven Therapeutics and Recludix Pharma; received clinical trial funding from Novartis and AstraZeneca; received royalties from patent 6958335 (Novartis exclusive license) and Oregon Health & Science University and Dana-Farber Cancer Institute (1 Merck exclusive license, 1 CytolImage, Inc. exclusive license, and 1 Sun Pharma Advanced Research Company nonexclusive license); and US patents 4326534, 6958335, 7416873, 7592142, 10473667, 10664967, and 11049247. R.L.L. is on the supervisory board of Qiagen; is a scientific advisor to Imago, Mission Bio, Syndax. Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics, and Isoplexis for which he receives equity support; receives research support from Ajax and AbbVie; has been a consultant for Incyte, Janssen, Morphosys, and Novartis; and has received honoraria from AstraZeneca and Kura for invited lectures and from Gilead for grant reviews. J.C.B. has received research support from Janssen Pharmaceuticals, Genentech, Acerta Pharma, and Pharmacyclics and has served on the advisory board of Syndax Pharmaceuticals. J.M.F. receives research support (to the institution) from Takeda. The remaining authors declare no competing financial interests.

**ORCID profiles:** A.N.S., 0000-0001-5134-7336; S.H.K., 0000-0002-4900-7145; M.D., 0000-0002-2987-1331; M.R.L., 0000-0002-9816-6302; E.T., 0000-0001-8844-2345; V.H.D., 0000-0003-0278-7727; M.C.F., 0000-0002-6652-3838; A.S.M., 0000-0002-8971-2199; B.J.D., 0000-0001-8331-8206.

**Correspondence:** Antoine N. Saliba, Mayo Clinic, 200 1st St SW, Rochester, MN 55905; email: [saliba.antoine@mayo.edu](mailto:saliba.antoine@mayo.edu).

## References

- Vasu S, Kohlschmidt J, Mrózek K, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. *Blood Adv*. 2018;2(13):1645-1650.
- Saliba AN, John AJ, Kaufmann SH. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. *Cancer Drug Resist*. 2021;4(1):125-142.
- Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. *Cancer*. 2016;122(22):3484-3491.
- Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. *Cancer Discov*. 2019;9(7):910-925.
- Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374(23):2209-2221.
- Badar T, Atallah E, Shallis RM, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival. *Am J Hematol*. 2022;97(7):E232-E235.
- Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. *Blood*. 2010;115(18):3796-3800.
- Knorr KL, Schneider PA, Meng XW, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. *Cell Death Differ*. 2015;22(12):2133-2142.
- Smith PG, Traore T, Grossman S, et al. Azacitidine/decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML models. *Blood*. 2011;118(21):578-578.
- Swords RT, Coutre S, Maris MB, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. *Blood*. 2018;131(13):1415-1424.
- Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. *Nat Med*. 2020;26(12):1852-1858.
- Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
- Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Adv*. 2020;4(22):5681-5689.
- Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. *Exp Cell Res*. 2000;256(1):42-49.
- Jin S, Cojocari D, Purkal JJ, et al. 5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. *Clin Cancer Res*. 2020;26(13):3371-3383.
- Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. *Genes Dev*. 2012;26(4):344-349.
- Solly F, Koering C, Mohamed AM, et al. An miRNA-DNMT1 axis is involved in azacitidine resistance and predicts survival in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia. *Clin Cancer Res*. 2017;23(12):3025-3034.
- Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. *Proc Natl Acad Sci U S A*. 2010;107(16):7473-7478.
- Sekeres MA, Girshova L, Doronin VA, et al. Pevonedistat (PEV) + azacitidine (AZA) versus AZA alone as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% marrow blasts: the randomized phase 3 PANTHER Trial (NCT03268954). *Blood*. 2021;138(suppl 1):242-242.